Journal of Community Genetics

, Volume 6, Issue 4, pp 343–349 | Cite as

Variants of unknown significance on chromosomal microarray analysis: parental perspectives

  • Stephanie Jez
  • Megan Martin
  • Sarah South
  • Rena Vanzo
  • Erin Rothwell
Original Article

Abstract

Chromosomal microarray is the recommended first-tier genetic test when a child presents with idiopathic developmental delay (DD), intellectual disability (ID), and/or autism spectrum disorder (ASD). Microarray may discover variants of unknown clinical significance (VUS) and been suggested to cause parental stress and anxiety. A retrospective, mixed methods study investigated parental perceptions of chromosomal microarray results that contain VUS. Surveys were sent to parents of children with DD/ID/ASD following a VUS result to seek information regarding parental understanding of the result, perceived value, and perceptions of child vulnerability and parental stress. Parents reported that chromosomal microarray was important for understanding their child’s diagnosis and they were satisfied with the information. A majority of parents reported high confidence in their ability to explain a VUS result to others. Of the parents who reported they received support, many reported that the support was from a genetic counselor. Based on these results, VUS results are important to parents of children with DD/ID/ASD and genetic counseling regarding VUS results contributes positively to both parental understanding and support.

Keywords

Chromosomal microarray analysis Variant of unknown significance Autism spectrum disorder Developmental delay Intellectual disability 

References

  1. National Human Genome Research Institute (NHGRI) (2004) Design considerations for a potential United States population-based cohort to determine the relationships among genes, environment, and health: Recommendations of an expert panel. www.genome.gov/pages/about/OD/ReportsPublications/PotentialUSCohort.pdf
  2. Aatre RD, Day SM (2011) Psychological issues in genetic testing for inherited cardiovascular diseases. J Am Heart Assoc 4:81–90Google Scholar
  3. Abidin RR (1995) Parenting stress index (PSI), 3rd edn. Psychologocal Assessment Resources, OdessaGoogle Scholar
  4. Ardern-Jones A, Kenen R, Lynch E, Doherty R, Eeles R (2010) Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals’ perspectives. Hereditary Cancer Clin Pract 8(1):1CrossRefGoogle Scholar
  5. Bell J, Sistermans E, Ramsden SC (2008) Practice guidelines for the interpretation and reporting of unclassified variants (UVs) in clinical molecular genetics. Clin Mol Genet Soc 1–6Google Scholar
  6. Coulter ME, Miller DT, Harris DJ et al (2011) Chromosomal microarray testing influences medical management. Genet Med 13:770–776CrossRefPubMedGoogle Scholar
  7. Forsyth BW, Horwitz SM, Leventhal JM, Burger J (1996) The child vulnerability scale: an instrument to measure parental perceptions of child vulnerability. J Pediatic Psychol 21(1):89–101CrossRefGoogle Scholar
  8. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST (2011) College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med 13:680–685CrossRefPubMedGoogle Scholar
  9. Makela NL, Birch PH, Friedman JM, Marra CA (2009) Parental perceived value of a diagnosis for intellectual disability (ID): a qualitative comparison of families with and without a diagnosis for their child’s ID. Am J Med Genet 149A(11):2393–2402CrossRefPubMedGoogle Scholar
  10. Manning M, Hudgins L (2010) Array-based technology and recommendations for utilization in medical genetics practice for detection for chromosomal abnormalities. Genet Med 12(11):742–745PubMedCentralCrossRefPubMedGoogle Scholar
  11. Miles MB, Huberman AM (1994) Qualitative data analysis. Sage, Thousand OaksGoogle Scholar
  12. Miller DT, Adam MP, Aradhya S, Biesecker LG et al (2010) Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86(5):749–764PubMedCentralCrossRefPubMedGoogle Scholar
  13. O’Neill S, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD (2009) Distress among women receiving uninformative < I > BRCA1/2</I > results: 12-month outcomes. Psycho-Oncology 18(10):1088–1096PubMedCentralCrossRefPubMedGoogle Scholar
  14. Reiff M, Bernhardt BA, Mulchandani S et al (2012) “What does it mean?”: uncertainties in understanding results of chromosomal microarray testing. Genet Med 14:251–258CrossRefGoogle Scholar
  15. Tsuchiya KD, Shaffer LG, Aradhya S, Gastier-Foster JM, Patel A, Rudd MK, Brothman AR (2009) Variability in interpreting and reporting copy number changes detected by array-based technology in clinical laboratories. Genet Med 11(12):867–873CrossRefGoogle Scholar
  16. Vos J, Otten W, van Asperen C, Jansen A, Marko F, Tibben A (2008) The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psychooncology 17:822–830CrossRefPubMedGoogle Scholar
  17. Whitmarsh I, Davis AM, Skinner D, Bailey DB (2007) A place for genetic uncertainty: parents valuing an unknown in the meaning of disease. Soc Sci Med 65:1082–1093PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Stephanie Jez
    • 1
  • Megan Martin
    • 2
  • Sarah South
    • 1
    • 3
  • Rena Vanzo
    • 2
  • Erin Rothwell
    • 4
  1. 1.Department of Medical Genetics, Department of PediatricsUniversity of UtahSalt Lake CityUSA
  2. 2.Lineagen, Inc.Salt Lake CityUSA
  3. 3.ARUP LaboratoriesUniversity of UtahSalt Lake CityUSA
  4. 4.College of Nursing, Division of Medical Ethics and HumanitiesUniversity of UtahSalt Lake CityUSA

Personalised recommendations